Iskandar Idris

Dr. Iskandar Idris is a Professor at the Division of Medical Sciences and Graduate Entry Medicine within the School of Medicine at the University of Nottingham, based at the Royal Derby Hospital in Derby, UK. His research focuses on diabetes management and complications, particularly examining renal and cardiovascular outcomes in patients with type 2 diabetes.

Dr. Idris specializes in:

• Comparative effectiveness of diabetes medications
• Chronic kidney disease progression in diabetic patients
• Cardiovascular outcomes associated with glucose-lowering therapies
• Real-world clinical evidence using large databases

His research demonstrates significant expertise in analyzing the renal protective effects of SGLT2 inhibitors compared to other antidiabetic medications, utilizing robust methodologies including propensity-score matching and sensitivity analyses across diverse patient populations.

Dr. Idris has received research support through the National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre and conducts work at the NIHR Nottingham Clinical Research Facilities.

He maintains active collaborations with major pharmaceutical companies, serving in multiple capacities:

• Advisory board member
• Speaker
• Recipient of research grants

His industry partnerships include Eli Lilly, Novo Nordisk, Merck Sharp & Dohme, AstraZeneca, Abbott Diabetes Care, Sanofi and Boehringer Ingelheim, reflecting his standing as a key opinion leader in diabetes therapeutics.